PapersPMID:34758791
The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials.
What moved
1 findingHow to read these marks →- Decreases waist circumference
moderate
“Compared to placebo controlled group, C. fimbriata extract significantly reduced WC by − 1.59 cm (95% CI, − 3.07, − 0.10, p = 0.041; I2 = 32%, p = 0.23) and WHR by − 0.06 (95% CI, − 0.12, − 0.01, p = 0.05; I2 = 92%, p = 0.0003) respectively.”
- Study
- meta-analysis
- Effect
- −1.59 mean difference, 95% CI −3.07 to −0.1
- Dose studied
- CFE capsules, 0.5 g twice daily or 1 g/day across the pooled trials (Table 1)
- Population
- Adults with overweight or obesity in placebo-controlled randomised trials of Caralluma fimbriata extract, pooled
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Clinical trials of Caralluma fimbriata extract in overweight or obese adults (BMI > 25 kg/m2), healthy adults, and children and adolescents with Prader-Willi syndrome
- Participants
- not reported
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 16